|
MATSUMOTO Etsuko
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Professor and Division head |
|
| Article types | Original article |
| Language | English |
| Peer review | Non peer reviewed |
| Title | Nationwide trends in utilization and expenditure of biologic agents approved for asthma in Japan: Insights from the national database (2014-2023). |
| Journal | Formal name：Respiratory investigation Abbreviation：Respir Investig ISSN code：22125353/22125345 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 63(5),pp.915-917 |
| Author and coauthor | Tomohiro Akaba†, Mitsuko Kondo, Osamitsu Yagi, Keiko Kan-O, Ken Arimura, Atsushi Kurokawa, Yuno Shiota, Naoko Arakawa, Yutaro Horie, Musashi Ueda, Etsuko Tagaya |
| Publication date | 2025/07 |
| Summary | Biologics have transformed the management of severe asthma; however, nationwide data on their use in Japan remain limited. We conducted a descriptive analysis using the NDB Open Database from fiscal years 2014-2023 to examine trends in the prescription volumes and costs for five approved biologics. Total prescriptions increased markedly from 81 450 in 2014 to >2 million in 2023, while total costs rose from 24.1 million to 973.3 million U.S. dollars. The proportion of outpatient self-injection prescriptions accounted for more than half of the prescriptions by 2023. These findings reflect the broader adoption of biologics supported by biomarker-driven treatment and expanded access through home administration. Although biologics offer clinical benefits, their growing use highlights the need to monitor their long-term costs and ensure their appropriate utilization. This study provides a nationwide overview of the biologics approved for asthma treatment and highlights key trends relevant to clinicians and policymakers. |
| DOI | 10.1016/j.resinv.2025.07.012 |
| PMID | 40716196 |